Hepatoblastoma is the most common type of liver cancer in children, with approximately 100 new cases diagnosed annually in the United States. It accounts for 43% of all pediatric liver tumors. Hepatoblastoma most frequently occurs in children under the age of 3 and is more common in Caucasians than in African Americans. It also occurs slightly more often in males than in females.
Hepatoblastoma often presents as a large, asymptomatic abdominal mass, typically discovered during a routine physical examination or incidentally by a parent. As the disease progresses, symptoms such as osteopenia, weight loss, anorexia (loss of appetite), nausea, vomiting, fever, and abdominal pain may develop. Children with hepatoblastoma may also exhibit normochromic normocytic anemia (characterized by pale skin and lips due to a reduced number of red blood cells) or jaundice (yellowing of the eyes and skin due to elevated bilirubin levels).
Hepatoblastoma occurs more frequently in patients with Beckwith-Wiedemann syndrome and familial adenomatous polyposis (FAP). Beckwith-Wiedemann syndrome is characterized by a large tongue, enlarged organs, increased body size, umbilical hernia, abdominal wall defects, and low blood sugar during infancy. FAP is an inherited disorder marked by the development of thousands of colon polyps, which, if untreated, will progress to colon cancer. Hepatoblastoma is also more common in premature infants and those born with very low birth weight.
A tissue sample is taken from the primary tumor to confirm diagnosis.
Surgery and chemotherapy are the primary treatment modalities for hepatoblastoma. Up to 85% of the liver can be safely removed during surgery, as the remaining liver is capable of regenerating within a few months. Pulmonary metastases present at diagnosis should also be surgically removed, if feasible. Multi-agent chemotherapy is typically administered both before and after surgery, as these tumors are highly responsive to chemotherapy. Liver transplantation may be considered for children with unresectable tumors.
Approximately 90% of children with resectable tumors are cured, while those with unresectable tumors have survival rates around 60%. Patients who present with metastatic disease at diagnosis have a long-term survival rate of about 25%.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania